Navigation Links
Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
Date:5/28/2009

--Data from Ongoing Glioblastoma Dosimetry Trial Accepted for Oral Presentation at 2009 Society of Nuclear Medicine Annual Meeting --

--Over 65 Recurrent GBM Patients in Phase I and Phase II Clinical Trials Have Received Cotara to Date, with a Good Safety Profile and Longer-Term Survivors Seen in All Studies--

TUSTIN, Calif., May 28 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today provided an update on progress in the company's clinical program for Cotara(R), a targeted monoclonal antibody-based therapy being tested in a Phase II trial as a potential new treatment for recurrent glioblastoma multiforme (GBM), a deadly form of brain cancer. The company also reported that patient enrollment in the final cohort of a second Cotara GBM trial, a dose confirmation and dosimetry study, is nearing completion and that interim data from this trial has been accepted for an oral presentation at the Society of Nuclear Medicine Annual Meeting to be held June 13-18, 2009.

More than 65 patients with recurrent GBM have received Cotara in the current and previous clinical studies. Localization and accumulation of the drug to the tumor have been excellent and longer-term survivors (greater than one year from the time of Cotara treatment) have been observed in all of the trials, with some GBM patients from early clinical studies now alive more than 8.5 years after treatment with Cotara. Expected survival for patients with GBM is approximately six months from time of disease recurrence.

In the ongoing Phase II safety and efficacy trial, over half of the 40 planned GBM patients have been dosed with Cotara and patient follow-up is continuing. Screening for the anticipated final patient in the dose confirmation and
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
2. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
3. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
4. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
7. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
8. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
9. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
10. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
11. Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has been a leading ... showing its latest designs of wedding dresses and launching a ... CEO, all the fresh new products are designed for 2015, ... 80% off. All the clothes from LunaDress follow up with ...
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that ... And for those same twenty-plus years, the team at Doctors ... with the best possible doctor. With the combined breadth ...
(Date:1/22/2015)... January 23, 2015 Recently, Weddingshe.com has added ... and has announced its highest annual revenues in the past ... its popular glamorous wedding dresses. , According to the sales ... wedding dress promotions for them in 2015. This point can ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... DIEGO, May 11 , WHAT: 211 San Diego executives ... organization is undertaking to make 211 a nationwide service, ... during, times of need, ... resources at Join Our Journey event. 211 San Diego also will, ...
... from Regence BlueCross BlueShield President and CEO Mark Ganz. ... of private-sector health industry leaders to decrease the U.S.,s annual ... $2 trillion over the next ten years:"I support the health ... nation. We are a country that spends more than ...
... Interfere with Prescribed TherapiesSACRAMENTO, Calif., May 11 The ... a national network of over 250 physicians with the ... approved medical treatments and therapies, today cited a recent ... a large number of physicians believe insurance companies are ...
... GAINESVILLE, Fla. University of Florida researchers have learned more ... may reveal as much about the human immune system as ... , In findings to be published this week in the ... Academy of Sciences , scientists describe how they looked at ...
... Healthcare Realty Trust Incorporated (NYSE: HR ) ... ended March 31, 2009. This dividend, in the amount ... to shareholders of record on May 22, 2009. The ... cash flows from operations determined in accordance with GAAP. ...
... incorrect but worrying findings rises 50 percent by the 14th ... The more cancer screening tests you undergo, the higher your ... , While that conclusion may seem like common sense, ... the authors of a study in the May/June issue of ...
Cached Medicine News:Health News:211 San Diego Provides Support to San Diegans in Times of Crisis 2Health News:Regence Optimistic About Health Industry Leaders' Pledge to Cut Health Care Costs 2Health News:Alliance for Patient Access Wants Health Care Code of Conduct 2Health News:Scientists discover how smallpox may derail human immune system 2Health News:Healthcare Realty Trust Announces First Quarter Dividend 2Health News:Healthcare Realty Trust Announces First Quarter Dividend 3Health News:Healthcare Realty Trust Announces First Quarter Dividend 4Health News:More Cancer Tests Mean More False-Positive Results 2Health News:More Cancer Tests Mean More False-Positive Results 3
(Date:1/23/2015)... ORLANDO, Fla. and DUBLIN , ... of the agreement with KRS Global Biotechnology, Inc. for the ... will be compounded for shipment in the United ... 503B FDA approved Outsourcing Facility capable of compounding naltrexone tablets ...
(Date:1/23/2015)... , Jan. 23, 2015  iMD Companies, Inc. (ICBU) has ... increase market share and grab a foothold in the hydroponic, ... production capabilities and a presence in the sector, and recently ... the growth of hemp and medical marijuana, iMD is committing ...
(Date:1/23/2015)... plc (NYSE: MNK ) announced today that ... program. The open-ended authorization permits the company to repurchase ... "Funding additional initiatives and seeking attractive ... to pursue a range of focused growth strategies," said ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... Overall survival data in locally advanced pancreatic cancer patients ... Cancer Clinical Trial with TNFerade(TM) (PACT) were presented yesterday ... Meeting in Orlando, FL. , , (Logo: ... , The poster , entitled ...
... at Heart Failure Congress 2009 Demonstrate Promising Safety and ... 1 Corthera Inc. today announced that the results ... II portion of a Phase II/III multicenter, randomized, double-blind, ... for the treatment of acute heart failure (AHF), was ...
Cached Medicine Technology:TNFerade(TM) Phase III Data Presented at ASCO 2TNFerade(TM) Phase III Data Presented at ASCO 3Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables 2Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables 3Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables 4Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables 5
... is a single-use device that produces ... thermal spread and vapor sealing of ... can be used for resection of ... It is also an excellent tool ...
... PK Plasma V is a single ... tissue removal with minimal thermal spread and ... adenoma in the treatment of BPH, without ... vaporization of the prostate (PKVP), the Plasma-V ...
Medium Clip Appliers. American-made stainless steel, 6" long, curved tip. For use with VE-6-25 and VE-6-10 titanium surgical clips only....
Li Brand™ Surgical Hemostat. ("dissecting clamp") For NSV and other procedures....
Medicine Products: